These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 890699)

  • 1. A hypothesis concerning possible new derivatives of daunorubicin and adriamycin with enhanced DNA-binding properties.
    Neidle S
    Cancer Treat Rep; 1977 Aug; 61(5):928-9. PubMed ID: 890699
    [No Abstract]   [Full Text] [Related]  

  • 2. Interaction of new derivatives of daunorubicin and adriamycin with DNA.
    Arlandini E; Vigevani A; Arcamone F
    Farmaco Sci; 1977 May; 32(5):315-23. PubMed ID: 862886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin.
    Supino R; Necco A; Dasdia T; Casazza AM; Di Marco A
    Cancer Res; 1977 Dec; 37(12):4523-8. PubMed ID: 922737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between activity and amino sugar stereochemistry of daunorubicin and adriamycin derivatives.
    Di Marco A; Casazza AM; Gambetta R; Supino R; Zunino F
    Cancer Res; 1976 Jun; 36(6):1962-6. PubMed ID: 773533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New antitumor anthracyclines.
    Arcamone F
    Lloydia; 1977; 40(1):45-66. PubMed ID: 875639
    [No Abstract]   [Full Text] [Related]  

  • 6. DNA complexing antibiotics: daunomycin, adriamycin and their derivatives.
    Marco A; Arcamone F
    Arzneimittelforschung; 1975 Mar; 25(3):368-74. PubMed ID: 1174034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiol-dependent DNA damage produced by anthracycline-iron complexes. The structure-activity relationships and molecular mechanisms.
    Muindi J; Sinha BK; Gianni L; Myers C
    Mol Pharmacol; 1985 Mar; 27(3):356-65. PubMed ID: 2983184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adriamycin (NSC-123127) and its analogs.
    Henry DW
    Cancer Chemother Rep 2; 1974 Dec; 4(4):5-9. PubMed ID: 4451911
    [No Abstract]   [Full Text] [Related]  

  • 9. Cellular pharmacology of N,N-dimethyl daunorubicin and N,N-dimethyl adriamycin.
    Egorin MJ; Clawson RE; Ross LA; Bachur NR
    Cancer Res; 1980 Jun; 40(6):1928-33. PubMed ID: 7371027
    [No Abstract]   [Full Text] [Related]  

  • 10. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The discovery of daunorubicin.
    Di Marco A; Cassinelli G; Arcamone F
    Cancer Treat Rep; 1981; 65 Suppl 4():3-8. PubMed ID: 7049379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of anthracycline--DNA complexes by circular dichroism.
    Rizzo V; Penco S; Menozzi M; Geroni C; Vigevani A; Arcamone F
    Anticancer Drug Des; 1988 Aug; 3(2):103-15. PubMed ID: 3165639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fate of DNA and its complexes with daunorubicin and adriamycin in rat fibroblasts [proceedings].
    Noël G; Trouet A
    Arch Int Physiol Biochim; 1977 Feb; 85(1):189-9. PubMed ID: 68743
    [No Abstract]   [Full Text] [Related]  

  • 14. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
    Animati F; Arcamone F; Bigioni M; Capranico G; Caserini C; De Cesare M; Lombardi P; Pratesi G; Salvatore C; Supino R; Zunino F
    Mol Pharmacol; 1996 Sep; 50(3):603-9. PubMed ID: 8794900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrostatic and non-electrostatic contributions to the binding free energies of anthracycline antibiotics to DNA.
    Baginski M; Fogolari F; Briggs JM
    J Mol Biol; 1997 Nov; 274(2):253-67. PubMed ID: 9398531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives.
    Ghirmai S; Mume E; Tolmachev V; Sjöberg S
    Carbohydr Res; 2005 Jan; 340(1):15-24. PubMed ID: 15620662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adriamycin and daunorubicin disposition in the rabbit.
    Bachur NR; Hildebrand RC; Jaenke RS
    J Pharmacol Exp Ther; 1974 Nov; 191(2):331-40. PubMed ID: 4417723
    [No Abstract]   [Full Text] [Related]  

  • 18. Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety.
    Di Marco A; Casazza AM; Dasdia T; Necco A; Pratesi G; Rivolta P; Velcich A; Zaccara A; Zunino F
    Chem Biol Interact; 1977 Dec; 19(3):291-302. PubMed ID: 597963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intercalation with DNA is a prerequisite for daunomycin, adriamycin and its congeners in inhibiting DNAase I.
    Facchinetti T; Mantovani A; Cantoni L; Cantoni R; Salmona M
    Chem Biol Interact; 1978 Jan; 20(1):97-102. PubMed ID: 630649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA base sequence preference for adriamycin and nogalamycin binding.
    Choudhury K; Chakraborty R; Dhar TC; Neogy RK
    Indian J Biochem Biophys; 1985 Jun; 22(3):166-72. PubMed ID: 4077090
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.